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Available online 26 September 2016Background and purpose: Glabridin is a major ﬂavonoid in Glycyrrhiza glabra (licorice) root, a traditional Asian
medicine. Glabridin is reported to have anti-atherogenic, anti-inﬂammatory and anti-nephritic properties; how-
ever its effects on vascular tone remain unexplored.
Experimental approach: We examined the effect of glabridin on rat main mesenteric artery using isometric
myography and also ELISA to measure cGMP levels.
Key results:Glabridin (30 μM) relaxed arteries pre-constrictedwith the thromboxane A2 analog U46619 (0.2 μM)
by ~60% in an endothelium-independent manner. Relaxation to 30 μMglabridin was abolished by the guanylate
cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (1 μM) and by the BKCa channel blocker
tetraethyammonium (1mM) but was unaffected by the estrogen receptor antagonist ICI182780. The concentra-
tion-response curve to glabridin (0.1 to 30 μM) was downshifted by the KATP channel blocker glibenclamide
(10 μM), the KV channel blocker 4-aminopyridine (300 μM), and the KIR blocker BaCl2 (30 μM). In U46619-
contracted arteries partially relaxed by 0.1 μM sodium nitroprusside, application of 10 and 30 nM glabridin
caused additional vasorelaxation. Glabridin (30 μM) approximately doubled tissue [cyclic GMP]. Application of
the phosphodiesterase inhibitor isobutylmethylxanthine caused amuch larger rise in [cyclic GMP], and glabridin
failed to cause vasorelaxation or a further rise in [cGMP] when co-applied with IBMX.
Conclusions and implications:Vasorelaxation to glabridin is dependent on the opening of K+ channels, particularly
BKCa, probably caused by a rise in cellular [cyclic GMP] owing to phosphodiesterase inhibition. In the presence of
sodium nitroprusside an effect of glabridin is observed at nM concentrations, similar those measured in plasma
following human ingestion of licorice ﬂavonoid oil.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Rat1. Introduction
The isoﬂavone glabridin is an important constituent of licorice root
(Glycyrrhiza glabra), from which it was ﬁrst isolated in 1976 [1]. Prepa-
rations containing Glycyrrhiza glabra have been used by Indian and
Chinese medicine for centuries as a treatment for many diseases,
including ulcers, bronchitis and bacterial infections, and glabridin
has anti-oxidant, anti-inﬂammatory and skin-whitening properties,
providing a rationale for its inclusion in many cosmetic preparations.
Moreover, Glavonoid®, a standardised polyphenol extract of licorice
root containing 3% glabridin, is being marketed as a food supplement
and anti-obesity agent, and is added to yoghurt and fruit juices in
many Western countries.
As described in a recent review by Simmler and colleagues [2], a
burgeoning literature comprising studies in vitro and in animals inon).
. This is an open access article undervivo has shown that glabridin has anti-inﬂammatory, anti-atherogenic,
estrogenic, neuroprotective, and anti-osteoporetic actions. It is however
unclear towhat extent these effects contribute to the putative beneﬁcial
actions of licorice-derived preparations because most studies have
employed micromolar concentrations of glabridin, whereas its likely
plasma concentration range in humans following ingestion of licorice-
derived products is likely to be in the low nanomolar range [2]. An ex-
ception to this, however, is the glabridin-induced activation of estrogen
receptors in vascular smoothmuscle, which has been observed to occur
at concentrations as low as 10 nM [3].
In view of the widespread and long-standing use of preparations
containing Glycyrrhiza glabra and the increasing use of glabridin-
enriched extracts as food supplements and ingredients, it is noteworthy
that very little is known about its acute effects on the vasculature.More-
over, Tominaga et al. (2009) have demonstrated that ingestion of
glabridin for 8 weeks signiﬁcantly reduced BMI and visceral fat in
human volunteers [4], implying that glabridinmight be useful as a treat-
ment for obesity. Considering that obesity is very common in thosewiththe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tion of glabridin will increase in such patients, in which case it is impor-
tant that potential effects of this agent on the cardiovascular system be
understood. We therefore examined the effect of glabridin in rat main
mesenteric artery using a small vessel isometric myograph, and report
here for theﬁrst time that glabridin acts as a cGMP-dependent vasodilator.
2. Methods
2.1. Animal welfare and ethical statement
This study conformswith theGuide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publica-
tion No. 85–23, revised 1996) and is in accordance with UK Animals
(Scientiﬁc Procedures) Act, 1986, Amendment Regulations (SI 2012/
3039). Male Wistar rats (200–300 g; 6–8 weeks old) were killed by le-
thal injection (i.p.) of sodium thiopental.
2.2. Mounting of mesenteric arteries and measurement of tension
development
Intestines were excised and the main mesenteric artery and its pri-
mary branches were removed, placed in physiological salt solution
(PSS), containing in mM: NaCl 118; NaHCO3 24; KCl 4; CaCl2 1.8;
MgSO4 1; NaH2PO4 0.43; and glucose 5.56, and the main mesenteric ar-
tery was freed of surrounding adipose tissue, cut into rings and
mounted on a conventional small vessel wire myograph (Danish Myo
Technology, Aarhus, Denmark). Tension was recorded at a frequency
of 1 Hz. Mesenteric artery rings were stretched to give a basal tension
of 2–3mN, andwere equilibratedwith three brief exposures to PSS con-
taining 80 mmol/l KCl (80KPSS; isotonic replacement of NaCl by KCl).
0.2 μM U46619 was then applied to give a near maximal contraction,
and endothelial integrity was conﬁrmed by recording vasorelaxation
to 10 μM carbachol. Followingwashout, arteries were again constricted,
with either 0.2 μM U46619 or 10 μM norepinephrine (NE). When the
tension had reached a maximum, the vasorelaxing effect of glabridin
was recorded as described in the Results. Where appropriate, the endo-
thelium was removed by rubbing the vascular lumen with a human
hair, and its functional absence was conﬁrmed by the absence of carba-
chol-induced relaxation. All drugs used in these studies were sourced
from Sigma-Aldrich, UK).
In order to study the concentration-dependency of glabridin-in-
duced vasorelaxation, the contraction toU46619 (orNE,when the effect
of glibenclamidewas being studied)was allowed to reach itsmaximum,
and then ascending concentrations of glabridin, (0.1–30 μM), were ap-
plied cumulatively at 15 min intervals, with the effect of glabridin
being recorded at the end of each interval. Because the contractions to
U46619 and NE demonstrated some intrinsic rundown, each arterial
ring inwhich glabridinwas studiedwas pairedwith an arterial segment
from the same animal in which the amplitude of the contraction to
U46619 or NE was recorded in the absence of glabridin at the same
times at which contraction was measured in the presence of glabridin
(i.e. a time control). The percent relaxation caused by glabridin was
then calculated as 100 × ((1− A)− (1− B)) / (1− A), where A was
the percent relaxation recorded at a given time in the time control seg-
ment and Bwas the percent relaxation observed at the same time in the
paired segment treated with glabridin.
2.3. Cyclic GMP measurements
Intracellular cyclic GMP (cGMP) in rat mesenteric arteries wasmea-
sured as previously described [5] with minor modiﬁcations. Endotheli-
um-intact arterial segments [approx. 5 mg each (wet weight)] were
equilibrated in PSS for 30min at 37 °C under continuous carbogen bub-
bling and were then exposed to U-46199 (200 nM; 10 min), glabridin
(30 μM; 20 min), U46199 (200 nM) followed by glabridin (30 μM;20 min), IBMX (200 μM; 30 min) and IBMX (200 μM; 10min) followed
by glabridin (30 μM; 20 min). DMSO (3 μl; 10 min) was added as a ve-
hicle control to a further group of tissues. Tissues were snap frozen in
liquid nitrogen immediately after treatment. The frozen tissues were
pulverized in a pre-chilled (with liquid nitrogen) pulverizer. The tissue
pellet was suspended in chilled 5% trichloro acetic acid (200 μl) and
vortexed vigorously and then centrifuged at 5000g for 10 min at 8 °C.
Supernatant thus obtainedwas extracted ﬁve timeswithwater-saturat-
ed diethyl ether and was then used for cGMP assay, using an ELISA kit
(Cayman Chemical Company, Ann Arbor, MI, USA), following the
manufacturer's instructions. Measurements were made in 3 aliquots
from each tissue, and resulting values were averaged to produce each
data point used in subsequent calculations. Tissue pellets obtained
after centrifugationwere dissolved in 0.5 NNaOH for protein estimation
by the BCAmethod and the concentration of cGMPwas expressed as pi-
comoles/mg protein.
2.4. Data analysis and statistical procedures
Results were generally analyzed using Student's unpaired or paired
t-test, as appropriate, with p b 0.05 taken to indicate statistical signiﬁ-
cance. Results are shown as mean ± SEM. The effects of antagonists
on the galbridin concentration-response relationship shown in Fig. 4
were analyzed using repeated measures ANOVA with a Bonferroni
post hoc test. GraphPad Prism version 7 was used for statistical analysis
and preparation of ﬁgures.
3. Results
Initial experiments revealed that 30 μMglabridin caused a rapid and
robust relaxation of mesenteric arteries constricted with 0.2 mM
U46619. Fig. 1A illustrates an example of the vasorelaxing effect of
30 μMglabridin in endothelium-intactmesenteric arteries (note the en-
dothelium-dependent relaxation of the U46619 contracture to 10 μM
acetylcholine; ACh). Similar responses to glabridinwere observed in en-
dothelium-intact mesenteric arteries which had been pre-treated with
300 μML-NAME and10 μM indomethacin to prevent the synthesis of ni-
tric oxide (NO) and prostacyclin (PGI2) respectively (Fig. 1B) and also in
the absence of endothelium (Fig. 1C). These data indicated that the en-
dothelium played no role in mediating glabridin-induced relaxation.
Fig. 2 presents evidence that relaxation induced by 30 μM glabridin
was strongly dependent on the opening of large-conductance Ca2+ acti-
vated K+ (BKCa) channels. As shown in Fig. 2A, glabridin caused no re-
laxation of U46619-constricted arteries in PSS in which the [K+] had
been raised to 15 mM in order suppress any hyperpolarization (and
resulting relaxation) associatedwith K+ channel opening. Glabridin-in-
duced relaxationwas also strongly inhibited in the presence of the BKCa
channel blocker tetraethylammonium (TEA; 1mM) (Fig. 2B). Converse-
ly, neither the KV channel antagonist 4-aminopyridine (4-AP; 300 μM)
nor the KIR channel blocker BaCl2 (30 μM) had any signiﬁcant effect on
the response to glabridin (Fig. 2C and D, respectively). The KATP channel
blocker glibenclamide was used in order to determine whether these
channels were involved in relaxation induced by 30 μM glabridin. Be-
cause glibenclamide blocks contractions induced by U46619 [6], NE
(10 μM) was used to elicit pre-constriction in these experiments. As
shown in Fig. 2E and F, glabridin-induced relaxation of the norepineph-
rine contraction, which was similar to that observed when U46619 was
used to cause preconstruction, was unaffected by glibenclamide.
Fig. 3 presents themean effects of endothelial denudation, the com-
bination of L-NAME and indomethacin, 15 mM K+ PSS, and the K+
channel blockers on the vasorelaxation measured 10 min after the ap-
plication of 30 μM glabridin.
Although the results shown in Figs. 2 and 3 indicate that BKCa chan-
nels play an overriding role in the response to 30 μM glabridin, they do
not rule out the possibility that other K+ channels might be involved in
the vasorelaxation caused by lower glabridin concentrations. We
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Fig. 1. Lack of involvement of the endothelium in glabridin-induced vasorelaxation. Representative traces illustrating the relaxation by 30 μM glabridin of mesenteric arteries
preconstricted with 0.2 μM U46619. A) endothelium-intact artery, B) endothelium-intact artery pretreated with 300 μM L-NAME and 10 μM indomethacin, C) endothelium-denuded
artery.
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ated vasorelaxation in the presence and absence of the K+ channel
blockers TEA, 4-AP, Ba2+ and glibenclamide. We similarly examined
the effect of 300 μM L-NAME and 10 μM indomethacin on the glabridin
concentration-response relationship.
As shown in Fig. 4, whereas the combination of L-NAME and indo-
methacin had no signiﬁcant effect on the glabridin concentration-re-
sponse curve, 4-AP, Ba2+ (Fig. 4A) and glibenclamide (Fig. 4B)
appeared to generally suppress vasorelaxation at lower glabridin con-
centrations. This attenuation of the response to glabridinwas not signif-
icant for individual concentrations of any of these three blockers with
the exception of the effect of glibenclamide on the response to 10 μM
glabridin. However the effect on the entire concentration-response
curve for each of these blockers, as assessed using repeated measures
ANOVA, was highly signiﬁcant. TEA, which had almost abolished the re-
sponse to 30 μM glabridin, had a similar effect over the entire range of
concentrations tested (Fig. 4A).
Although ≤1 μM glabridin often appeared to cause a concentration-
dependent vasorelaxation, this effect was not statistically signiﬁcant.
This may have been because its effect at these low concentrations was
slow and therefore difﬁcult to unambiguously distinguish from the grad-
ual intrinsic decay of the U46619 contraction. In order to determine
whether the possible effect of 1 μM glabridin on tension was real, we
therefore used a pre-treatment protocol, as illustrated in Fig. 5. In these
experiments, glabridin was applied at the peak of the U46619 contrac-
tion. 30 min later, U46619 and glabridin were washed out of the bath,
and 1 μM glabridin was immediately re-applied. Following a further
30 min incubation in glabridin, U46619 was again applied, and the
peak contraction was recorded. As shown in Fig. 5, the second U46619
contraction was smaller than the ﬁrst. In ﬁve similar experiments, the
amplitude of the U46619 contraction fell by 27.0 ± 6.8% in the presence
of glabridin (from 12.7 ± 1.4 to 9.4 ± 1.4 mN, p b 0.05 by paired t-test).Cyclic nucleotides are known to open BKCa channels present in vas-
cular smooth muscle. As shown in Fig. 6A and E, the guanylate cyclase
inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 1 μM)
abolished the effect of 30 μMglabridin. The efﬁcacy of this concentration
of ODQ against guanylate cyclase was evidenced by its ability to ablate
vasorelaxation elicited by the NO donor SNP (Fig. 6B, E). On the other
hand, the protein kinase A antagonist KT-5720 (1 μM, Fig. 5C) and the
estrogen receptor blocker ICI 182780 (10 μM; Fig. 6D, E) had no effect
on the relaxation to 30 μM glabridin. Further evidence that glabridin
was not acting via estrogen receptors is presented in Fig. 6F. Whereas
treatment of tissues with the selective estrogen receptor modulator ral-
oxifene (10 μM) attenuated the contraction induced by depolarization
with 80 mM KPSS (49.5), glabridin (30 μM) did not affect the response
to highK+ (2.4±3.3% decrease, n=4, ns vs control, p b 0.05 vs effect of
raloxifene).
The results described abovewere consistentwith the possibility that
glabridin was causing vasorelaxation via a cGMP-dependent activation
of K+ channels. In this case, it would be predicted that glabridin should
increase the cellular concentration of cGMP. As illustrated in Fig. 7A, a
15 min treatment with 30 μM glabridin caused a signiﬁcant increase
in the cyclic GMP content of segments of mesenteric artery, which
was similar in the presence and absence of 200 nMU46619, which itself
had no effect on the cGMP content.
The twomost straightforward possible explanations for the ability of
glabridin to raise the cGMP content of the arteries were that it was ei-
ther stimulating guanylate cyclase or inhibiting phosphodiesterase
(PDE). In this case, we reasoned that if glabridin was acting as a PDE in-
hibitor it would exert no effects on vascular tone or tissue cGMP if PDE
was already maximally inhibited. Conversely, if glabridin was acting by
stimulating guanylate cyclise, its effects on vascular tone and [cGMP]
should persist (and might even be potentiated) if it was applied when
PDE was already blocked. We therefore examined the effects of
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Fig. 2. Effects of 15 mM K+ and K+ channel antagonists on glabridin-induced vasorelaxation. Representative traces illustrating the effect of 30 μM glabridin on the U46619-induced
contraction in the presence of (A) PSS containing 15 mM K+, (B) 1 mM TEA, (C) 300 μM 4-AP, and (D) 30 μM Ba2+. E) Representative traces showing the effect of 30 μM glabridin on
the norepinephrine-induced contraction in the absence (left) and presence (right) of 10 μM glibenclamide.
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selective cGMP PDE inhibitor isobutylmethylxanthine (IBMX).
Fig. 8A shows that treatment with 100 μM IBMX was enough to vir-
tually abolish the U46619 contraction to 200 nM U46619. However,
even in the presence of a somewhat higher concentration of IBMX
(200 μM), it was possible to evoke a contraction whichwas of sufﬁcient
amplitude to be measured accurately if a very high concentration of
U46619 (30 μM)was used (Fig. 8B). This residual contraction was unaf-
fected by the application of 30 μMglabridin (Fig. 8B). On the other hand,
subsequent application of the nitric oxide donor SNP (300 nM), which
would be expected to stimulate guanylate cyclase, caused a marked va-
sodilation. These results are summarised in Fig. 8C. Fig. 8D illustrates the
effect of 200 μM IBMX and the combination of 200 μM IBMX and 30 μM
glabridin on the cGMP content of segments of mesenteric artery. IBMXcaused the expected large rise in [cGMP], but glabridin exerted no fur-
ther effect.
In light of the possibility that glabridin might be acting as a PDE in-
hibitor, we reasoned that the vasorelaxing effects of low concentrations
of glabridin might be potentiated if cGMP levels were ﬁrst elevated by
the NO donor sodium nitroprusside (SNP). We therefore applied
100 nMSNP at the peak of the U46619 contraction to evoke an immedi-
ate relaxation of 30–40%, and then applied 10 and 30 nMglabridin. Ten-
sion levels in the presence of glabridinwere compared to tension during
the same period in control tissues in which only SNPwas added. Results
from 7 tissues treated with glabridin were normalized and averaged,
and are illustrated in Fig. 9A. It is evident that whereas the level of ten-
sion tended to recover slightly in the presence of SNP only, tension fell
in a stepwise manner after application of 10 and 30 nM glabridin. Fig.
µµ
µ µ µ
Fig. 3.Mean effect of 30 μMglabridinunder control conditions and following interventions
designed to block endothelium–dependent or K+ channel-mediated vasorelaxation.
Mean ± SEM percent relaxation induced by 30 μM glabridin under the various
conditions illustrated by the traces in Figs. 1 and 2. Asterisks indicate that the effect of
glabridin under a particular condition was signiﬁcantly (p b 0.05) different than that
recorded under control conditions (i.e. endothelium-intact mesenteric arteries
preconstrictedwith 0.2 μMU46619). Each bar represents the results of 6–11 experiments.
A
B
Fig. 4.Effects of blockers on the concentration-response curve for glabridin vasorelaxation.
(A)Mean± SEMpercent relaxation of the contraction to 0.2mMU46619 induced by 0.1–
30 μM glabridin under control conditions and in the presence of 300 μM L-NAME and
10 μM indomethacin, 1 mM TEA, 300 μM 4-AP, and 30 μM Ba2+. (B) Mean ± SEM
percent relaxation of the contraction to 10 μM NE induced by 0.1–30 μM glabridin under
control conditions and in the presence of 10 μM glibenclamide. For both panels, * to the
right of the point at 30 μM glabridin indicates a signiﬁcant inhibition of the response to
glabridin over the range of concentrations examined, whereas # adjacent to a point on
the curve indicates a signiﬁcant effect of the blocker at that concentration of glabridin.
Vasorelaxation was corrected for intrinsic time-dependent rundown of the contractile
response as described in the Methods. Each curve represents the results of 5–8
experiments.
µ
Fig. 5. Effect of pretreatment with 1 μM glabridin on the amplitude of the U46619
contraction. Representative trace illustrating the effect of 60 min pretreatment with
1 μM glabridin on the contraction evoked by 0.2 μM U46619.
30 D. Chanda et al. / Life Sciences 165 (2016) 26–349B and C depict individual experiments in which glabridin was either
applied or not applied after SNP. Fig. 9D represents the mean relaxation
observed when the effects of SNP or SNP + glabridin had stabilized
(left), or during the same time intervals in arteries to which only SNP
had been added (right). Fig. 9E shows the mean increase in relaxation
between these time periods in the presence and absence of glabridin.
Glabridin relaxed the arteries signiﬁcantly at both 10 and30 nM,where-
as no signiﬁcant time-dependent relaxation was observed with SNP
alone; moreover this difference was signiﬁcant. These data indicate
that glabridin exerts a small but measurable effect on mechanisms con-
trolling vascular tone at concentrations which are relevant to the use of
this drug as a possible therapeutic agent [7].
4. Discussion and conclusions
Glabridin has been shown to have several effects which could be
beneﬁcial for the cardiovascular system, although the extent to which
these contribute to the putative therapeutic actions of licorice root is un-
clear. Notably, in vitro and in vivo studies show that glabridin inhibits
low density lipoprotein oxidation and atherogenesis [8], possibly by
inhibiting NADPH oxidase [9] or by increasing the expression of antiox-
idant enzymes in macrophages [10]. Somjen et al., (2004) also showed
that 30 nMglabridin caused DNA synthesis and a stimulation of creatine
kinase activity in an endothelial cell line (ECV-304) and cultured uterine
artery smooth muscle cells [3]. Both effects were blocked by the estro-
gen receptor antagonist raloxifene. Moreover, glabridin has been
shown to reduce adiposity in obese rodents, an actionwhichmay result
from an inhibition of mitochondrial ATP synthesis with a consequent
stimulation of AMP kinase [11].
Our observations indicate that glabridin evokes vasorelaxation by
opening K+ channels, an effect which would be predicted to cause vas-
cular smooth muscle cell hyperpolarization, resulting in the closure of
voltage-gated Ca2+ channels and, as a consequence, a fall in [Ca2+].
This would explain the abolition of the response to glabridin in PSS con-
taining 15 mM K+, at which concentration smooth muscle hyperpolar-
ization beyond−50mV should be prevented [12]. The virtual abolition
of the glabridin-induced relaxation by TEA, which is relatively selective
for BKCa channels at the concentration we employed (1 mM) [13], indi-
cates a predominant role for this type of K+ channel. However, relaxa-
tion to lower concentrations of glabridin was also attenuated by
blockers of voltage-gated (KV), inwardly rectifying (KIR) and ATP-sensi-
tive (KATP) K+ channels, suggesting that the opening of these channels
was reinforcing BKCa-induced hyperpolarization.
Relaxationwas blocked by the guanylate cyclase inhibitor ODQ, indi-
cating that glabridin-induced relaxation was likely occurring via cGMP.
This possibility was supported by the ﬁnding that glabridin caused an
approximately two-fold increase in the cGMP content of arterial seg-
ments. There is abundant evidence that raising VSMC cGMP levels re-
sults in the activation of K+ channels. A link between the activation of
the cGMP/G kinase pathway and the opening of BKCa channels has
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Fig. 6. Effects of ODQ, KT5720 and ICI 182780 on vasorelaxation of the contraction to 200 nM U46619 by 30 μM glabridin. A) Representative trace showing the effect of glabridin in the
presence of 1 μM ODQ. B) Representative traces showing the effect of SNP in the absence (black line) and presence (grey line) of 1 μM ODQ. Representative traces showing the effect
of glabridin in the presence of KT5720 (C; 1 μM) and ICI 182780 (D; 10 μM). E) Average relaxation of the U46619 contraction by glabridin in the absence of another drug, and in the
presence of KT5720, ODQ, and ICI 182780). Numbers of experiments used to calculate the results are shown over the bars, and asterisks represent a signiﬁcant difference vs the
control relaxation. (F) Representative traces depicting the effect on the contraction evoked by 80KPSS of preincubation of arterieswith 10 μMraloxifene (top) or 30 μMglabridin (bottom).
31D. Chanda et al. / Life Sciences 165 (2016) 26–34been well characterized [14,15], and there is also evidence, albeit less
well documented, that this second messenger system can activate KV
[16,17], KIR, [17] and KATP [17–19] channels in vascular smooth muscle.
Glabridinmight increase [cGMP] either bypromoting its synthesis or
by inhibiting its breakdown, e.g. by acting as a PDE inhibitor. In the for-
mer case, it would be predicted that inhibition of PDE would not pre-
vent, or would enhance, glabridin's actions, whereas in the latter one
might expect that glabridin would have no effect. We observed that fol-
lowing treatment of mesenteric arteries with 200 μM IBMX, glabridin
was no longer able to cause relaxation. Moreover, the combination of
glabridin and IBMX caused an increase in tissue [cGMP] which wassimilar to that induced by IBMX alone. This concentration of IBMX
would be expected to fully block PDE5 [20], the main PDE involved in
metabolizing cGMP in the vasculature [21]. These data therefore are
consistent with the possibility that glabridin is acting as a PDE inhibitor.
A recent comprehensive reviewof thepharmacodynamics and phar-
macokinetics of glabridin [2] has highlighted the fact that glabridin's an-
tioxidant properties, which are thought to be responsible formany of its
other biological effects, have been observed in studies employingmicro-
molar concentrations,whereas its plasma concentrations are likely to be
closer to 10 nM. On the other hand, concentrations of glabridin in the
nanomolar range stimulated estrogen receptors [3], leading Simmler
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Fig. 7. Effects of 30 μM glabridin on cGMP levels in rat mesenteric artery segments in the
presence and absence of U46619. * indicates a signiﬁcant effect of glabridin on [cGMP]
compared to the corresponding control. Numbers of experiments (i.e. measurements in
individual artery segments) used to calculate the results are shown over the bars, and
asterisks represent a signiﬁcant difference vs the control cGMP level.
32 D. Chanda et al. / Life Sciences 165 (2016) 26–34et al. to suggest that, of all the documented effects of glabridin, its estro-
genic properties were most worthy of further study [2]. As stimulation
of estrogen receptors has been shown to cause acute vascular relaxation
via a mechanism which is dependent on cyclic GMP and BKCa channels
[22–25] we examined whether the vasorelaxation to glabridin was
blocked by the estrogen receptor antagonist ICI 182780, and found
that it was not. However the lack of effect of ICI 182780 did not provide
deﬁnitive evidence against a role for estrogen receptors, because al-
though this drug was observed to block 17β-estradiol -inducedC D
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Fig. 8. Effect of IBMX on glabridin-induced responses. A) Representative trace showing the effec
sequential addition of 30 μMglabridin and 100 nMSNP on the contraction evoked by 30 μMU46
when applied in the presence of 200 nMU46619 or 200 μMIBMXand 200nMU46619, and vaso
and 200nMU46619. * indicates a signiﬁcant block of the response to glabridin or SNP in thepres
in the absence and presence of 30 μMglabridin. * indicates a signiﬁcant increase in cGMP conten
individual arterial segments) used to calculate the results are shown over the bars.vasorelaxation in some arteries [19,26], it was reported to have no effect
on the relaxation to either 17β-estradiol or the selective estrogen recep-
tor modulator raloxifene in rat superior mesenteric arteries [25]. Chan
and colleagues similarly showed that dilation by raloxifene of third-
order rat mesenteric arteries was insensitive to ICI 182780, and that
this effect of raloxifene was almost completely suppressed by L-NAME
[27]. However, we sawnoeffect of L-NAME on the response to glabridin.
More importantly, raloxifene was shown by Tsang et al. (2004) to relax
depolarization-induced contractions in rat cerebral arteries [28], and
whereas we similarly found that raloxifene markedly attenuated the
contraction evoked by 80KPSS in rat mesenteric arteries, glabridin had
no effect on the high K+ contraction. On balance, therefore, the results
with ICI 182780 and raloxifene imply strongly that glabridin was not
causing vasorelaxation by stimulating estrogen receptors.
Glabridin concentrations in the plasma following ingestion of lico-
rice root-containing preparations are not known. Aoki et al., (2007) es-
timated steady state plasma glabridin concentrations were between 0.6
and 2.4 ng/ml (2–7 nM) in healthy human subjects who ingested
1200 mg of licorice ﬂavonoid oil (LFO; contained ~12 mg of glabridin)
daily for several weeks, a dose which was apparently tolerated with
no ill effects [7]. Tominaga et al., 2009 used a similar dose (900 mg
daily) to show in a randomized trial that LFO caused a signiﬁcant reduc-
tion in BMI and visceral fat [4]. Althoughwe did not attempt to examine
the effect of glabridin applied on its own at concentrations below
0.1 μM, its application at concentrations of 10 and 30 nM caused further
vasorelaxation when added in the presence of 100 nM SNP. It therefore
seems that glabridin is able to exert measurable acute effects on vascu-
lar tone at plasma concentrations close to thosewhich could occur in in-
dividuals ingesting glabridin-enriched foods or supplements.
In conclusion, our results indicate that glabridin induced a vasore-
laxation of rat mesenteric arteries which was associated with the0.
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33D. Chanda et al. / Life Sciences 165 (2016) 26–34opening of K+ channels and a concomitant rise in tissue cGMP levels.
Glabridin was not able to cause vasodilation, or a further rise in cGMP,
in the presence of the non-selective PDE inhibitor IBMX, consistent
with the possibility that it was acting as a PDE inhibitor. In the presence
of SNP, a measurable vasorelaxing effect of glabridin was observed at
nanomolar concentrations, implying that glabridinmay be able to inﬂu-
ence vascular tone at plasma concentrations which might be attained
following its consumption, particularly in the presence of anotherdrug which has raised cGMP levels. Veriﬁcation of the relevance of
these ﬁndings to the use of glabridin as a food supplement or an aid to
weight loss [4] must, however, await future studies in humans.Conﬂict of interest
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